Robert J Adelman - Net Worth and Insider Trading

Robert J Adelman Net Worth

The estimated net worth of Robert J Adelman is at least $4,283 dollars as of 2024-12-28. Robert J Adelman is the Director, 10% Owner of Metacrine Inc and owns about 3,059,123 shares of Metacrine Inc (MTCR) stock worth over $4,283. Details can be seen in Robert J Adelman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert J Adelman has not made any transactions after 2020-09-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Robert J Adelman

Robert J Adelman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert J Adelman owns 10 companies in total, including Metacrine Inc (MTCR) , Checkmate Pharmaceuticals Inc (CMPI) , and ALX Oncology Holdings Inc (ALXO) among others .

Click here to see the complete history of Robert J Adelman’s form 4 insider trades.

Insider Ownership Summary of Robert J Adelman

Ticker	Comapny	Transaction Date	Type of Owner
MTCR	Metacrine Inc	2020-09-18	director & 10 percent owner
CMPI	Checkmate Pharmaceuticals Inc	2020-08-06	10 percent owner
ALXO	ALX Oncology Holdings Inc	2020-07-16	10 percent owner & other: See Remarks
		2020-07-01	10 percent owner
		2019-03-27	director & 10 percent owner
		2008-11-14	director & 10 percent owner
		2021-04-22	10 percent owner
		2022-05-25	10 percent owner
		2021-10-20	10 percent owner & other: See Remarks
		2023-09-14	10 percent owner

Robert J Adelman Latest Holdings Summary

Robert J Adelman currently owns a total of 1 stock. Robert J Adelman owns 3,059,123 shares of Metacrine Inc (MTCR) as of September 18, 2020, with a value of $4,283.

Latest Holdings of Robert J Adelman

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MTCR	Metacrine Inc	2020-09-18	3,059,123	0.00	4,283

Holding Weightings of Robert J Adelman

Robert J Adelman Form 4 Trading Tracker

According to the SEC Form 4 filings, Robert J Adelman has made a total of 1 transactions in Metacrine Inc (MTCR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Metacrine Inc is the acquisition of 230,000 shares on September 18, 2020, which cost Robert J Adelman around $3 Million.

Insider Trading History of Robert J Adelman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Robert J Adelman Trading Performance

GuruFocus tracks the stock performance after each of Robert J Adelman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert J Adelman is -12.87%. GuruFocus also compares Robert J Adelman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert J Adelman within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Robert J Adelman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Robert J Adelman

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	6.83
Relative Return to S&P 500(%)	1.88

Robert J Adelman Ownership Network

Ownership Network List of Robert J Adelman

No Data

Ownership Network Relation of Robert J Adelman

Robert J Adelman Owned Company Details

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

Robert J Adelman is the director & 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metacrine Inc Insider Transactions

No Available Data

What does Checkmate Pharmaceuticals Inc do?

Who are the key executives at Checkmate Pharmaceuticals Inc?

Robert J Adelman is the 10 percent owner of Checkmate Pharmaceuticals Inc. Other key executives at Checkmate Pharmaceuticals Inc include 10 percent owner Venbio Global Strategic Fund Ii L.p. , director & Chief Executive Officer Alan Bash , and 10 percent owner Novo Holdings A/s .

Checkmate Pharmaceuticals Inc (CMPI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Checkmate Pharmaceuticals Inc (CMPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Checkmate Pharmaceuticals Inc (CMPI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Checkmate Pharmaceuticals Inc (CMPI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Checkmate Pharmaceuticals Inc Insider Transactions

No Available Data

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

Robert J Adelman is the 10 percent owner & other: See Remarks of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include VP & Finance and CAO Shelly Pinto , Chief Medical Officer Sophia Randolph , and director & President and CEO Jaume Pons .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 145,903 shares made by Jaume Pons , a net sale of 14,288 shares made by Shelly Pinto , and a net sale of 18,243 shares made by Sophia Randolph .

In summary, during the past 3 months, insiders sold 0 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 30,000 shares, with a net purchase of 30,000 shares. During the past 18 months, 179,321 shares of ALX Oncology Holdings Inc (ALXO) were sold and 58,400 shares were bought by its insiders, resulting in a net sale of 120,921 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ALX Oncology Holdings Inc Insider Transactions

No Available Data

What does Akero Therapeutics Inc do?

Who are the key executives at Akero Therapeutics Inc?

Robert J Adelman is the 10 percent owner of Akero Therapeutics Inc. Other key executives at Akero Therapeutics Inc include Chief Scientific Officer Timothy Rolph , See Remarks Patrick Lamy , and Chief Development Officer Catriona Yale .

Akero Therapeutics Inc (AKRO) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in Akero Therapeutics Inc (AKRO). Other recent insider transactions involving Akero Therapeutics Inc (AKRO) include a net sale of 183,963 shares made by Jonathan Young , a net sale of 137,589 shares made by Catriona Yale , and a net sale of 449,744 shares made by Andrew Cheng .

In summary, during the past 3 months, insiders sold 431,340 shares of Akero Therapeutics Inc (AKRO) in total and bought 0 shares, with a net sale of 431,340 shares. During the past 18 months, 1,090,243 shares of Akero Therapeutics Inc (AKRO) were sold and 280,000 shares were bought by its insiders, resulting in a net sale of 810,243 shares.

Akero Therapeutics Inc (AKRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akero Therapeutics Inc Insider Transactions

No Available Data

What does Precision BioSciences Inc do?

Who are the key executives at Precision BioSciences Inc?

Robert J Adelman is the director & 10 percent owner of Precision BioSciences Inc. Other key executives at Precision BioSciences Inc include Interim CFO John Alexander Kelly , director & President and CEO Michael Amoroso , and General Counsel Dario Scimeca .

Precision BioSciences Inc (DTIL) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in Precision BioSciences Inc (DTIL). Other recent insider transactions involving Precision BioSciences Inc (DTIL) include a net sale of 38,263 shares made by Dario Scimeca , a net sale of 266,953 shares made by Michael Amoroso , and a net sale of 28,204 shares made by J. Jefferson Smith .

In summary, during the past 3 months, insiders sold 3,600 shares of Precision BioSciences Inc (DTIL) in total and bought 3,000 shares, with a net sale of 600 shares. During the past 18 months, 17,865 shares of Precision BioSciences Inc (DTIL) were sold and 6,000 shares were bought by its insiders, resulting in a net sale of 11,865 shares.

Precision BioSciences Inc (DTIL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Precision BioSciences Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

Robert J Adelman is the director & 10 percent owner of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Mark W Perry , 10 percent owner Krishna Kittu Kolluri , and 10 percent owner Newhall Charles W Iii .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does IPI Legacy Liquidation Co do?

Who are the key executives at IPI Legacy Liquidation Co?

Robert J Adelman is the 10 percent owner of IPI Legacy Liquidation Co. Other key executives at IPI Legacy Liquidation Co include 10 percent owner Vivo Capital Fund Viii, L.p. , CFO Michael Wayne Kalb , and VP & Controller & Interim CFO Rajiv Amin .

IPI Legacy Liquidation Co (IMPLQ) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in IPI Legacy Liquidation Co (IMPLQ). Other recent insider transactions involving IPI Legacy Liquidation Co (IMPLQ) include a net sale of 575,000 shares made by Vivo Capital Fund Viii, L.p. ,

In summary, during the past 3 months, insiders sold 0 shares of IPI Legacy Liquidation Co (IMPLQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 575,000 shares of IPI Legacy Liquidation Co (IMPLQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 575,000 shares.

IPI Legacy Liquidation Co (IMPLQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

IPI Legacy Liquidation Co Insider Transactions

No Available Data

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Robert J Adelman is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Venbio Global Strategic Gp Iii, L.p. , and 10 percent owner Venbio Global Strategic Fund Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elevation Oncology Inc Insider Transactions

No Available Data

What does Ventyx Biosciences Inc do?

Who are the key executives at Ventyx Biosciences Inc?

Robert J Adelman is the 10 percent owner & other: See Remarks of Ventyx Biosciences Inc. Other key executives at Ventyx Biosciences Inc include Chief Scientific Officer John Nuss , director & Chief Executive Officer Raju Mohan , and Chief Financial Officer Martin Auster .

Ventyx Biosciences Inc (VTYX) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in Ventyx Biosciences Inc (VTYX). Other recent insider transactions involving Ventyx Biosciences Inc (VTYX) include a net sale of 483,232 shares made by Nsv Partners Iii Lp , a net sale of 483,232 shares made by Somu Subramaniam , and a net purchase of 316,828 shares made by Raju Mohan .

In summary, during the past 3 months, insiders sold 13,161 shares of Ventyx Biosciences Inc (VTYX) in total and bought 630,000 shares, with a net purchase of 616,839 shares. During the past 18 months, 1,397,578 shares of Ventyx Biosciences Inc (VTYX) were sold and 630,000 shares were bought by its insiders, resulting in a net sale of 767,578 shares.

Ventyx Biosciences Inc (VTYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ventyx Biosciences Inc Insider Transactions

No Available Data

What does RayzeBio inc do?

Who are the key executives at RayzeBio inc?

Robert J Adelman is the 10 percent owner of RayzeBio inc. Other key executives at RayzeBio inc include 10 percent owner Viking Global Investors Lp , 10 percent owner Viking Global Opportunities Drawdown (aggregator) Lp , and 10 percent owner Goodman Corey S .

RayzeBio inc (RYZB) Insider Trades Summary

Over the past 18 months, Robert J Adelman made no insider transaction in RayzeBio inc (RYZB). Other recent insider transactions involving RayzeBio inc (RYZB) include a net purchase of 2,777,778 shares made by Viking Global Investors Lp , and a net purchase of 472,222 shares made by Maha Katabi .

In summary, during the past 3 months, insiders sold 0 shares of RayzeBio inc (RYZB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of RayzeBio inc (RYZB) were sold and 3,250,000 shares were bought by its insiders, resulting in a net purchase of 3,250,000 shares.

RayzeBio inc (RYZB)'s detailed insider trading history can be found in Insider Trading Tracker table.

RayzeBio inc Insider Transactions

No Available Data

Robert J Adelman Mailing Address

Above is the net worth, insider trading, and ownership report for Robert J Adelman. You might contact Robert J Adelman via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.

Discussions on Robert J Adelman

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.